My watch list  


Systematic (IUPAC) name
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
CAS number 54350-48-0
ATC code D05BB01
PubChem 3312
DrugBank APRD00966
Chemical data
Formula C23H30O3 
Mol. mass 354.483 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes Oral

Etretinate (trade name Tegison®) is a medication used to treat severe psoriasis. It was removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.

Additional recommended knowledge


  • Etretinate is a teratogen, and may cause birth defects long after use. Therefore, etretinate should only be used if one is never to get pregnant.
  • Etretinate should be avoided in children, as it may interfere with growth of bone.

Side effects

  • Hepatitis
  • Pseudotumor cerebri

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Etretinate". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE